Statement of Task:
Designing clinical trials to test the safety and efficacy of regenerative medicine therapies, such as gene- and gene-editing-based therapies, can be complex for several reasons including challenges with determining an optimal dosage, delivering the product effectively, and successfully recruiting patients to what may be “single chance” trials, to name a few. To explore the design complexities and ethical issues associated with clinical trials for these types of therapies, an ad hoc planning committee will hold a one-day public workshop in Washington, DC. Speakers at the workshop may be asked to discuss patient recruitment and selection for gene-based clinical trials, assessing the safety of new therapies, dose escalation, and ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The concept of repeat dosing and sensitization treatments may also be explored. A broad array of stakeholders may take part in the workshop, including academic and industry researchers, regulatory officials, clinicians, bioethicists, and individuals/patients and patient advocacy groups. The planning committee will develop the workshop agenda, select and invite speakers and discussants, and may moderate the discussions. A proceedings of the workshop will be prepared by a designated rapporteur in accordance with institutional policy and procedures.
BACKGROUND
As a way to define the scope of this workshop, the planning committee used the following definition of gene therapy from the FDA, which is “the administration of genetic material to modify or manipulate the expression of a gene product or to alter the biological properties of living cells for therapeutic use.” Similarly to the FDA the committee also considered any use of gene editing (techniques including CRISPR/Cas9 that allow for precise changes in the nucleic acids of a person, animal, or other living organism) to be a gene-based therapy. The workshop scope may also include discussions of topics related to gene therapies in the context of other available and potentially curative treatments (e.g. bone marrow transplantation for hemoglobinopathies) and the decision-making process faced by patients and clinicians.

AGENDA
8:30 a.m. Opening Remarks

KATHY TSOKAS, Forum Co-Chair
Regulatory Head of Regenerative Medicine & Advanced Therapy
Johnson & Johnson

8:35 a.m. Charge to Workshop Speakers and Participants

KRISHANU SAHA, Workshop Co-Chair
Assistant Professor
University of Wisconsin-Madison

8:45 a.m. Trial by “Firsts”: Lessons from the Frontlines of Clinical Trials in Gene Therapy

KATHERINE HIGH
President and Head of R&D
Spark Therapeutics

9:05 a.m. Clarifying Questions from Workshop Participants

SESSION I: DEVELOPING FIRST IN HUMAN GENE THERAPY CLINICAL TRIALS

Session Objective:
- Explore the issues arising in the design of early stage clinical gene therapy trials, including choice of endpoints, relevance and requirements for preclinical data, and identifying and using appropriate controls or natural history datasets.

Session Moderator: Cindy Dunbar, NHLBI, NIH

9:15 a.m. JONATHAN KIMMELMAN
Director of Biomedical Ethics Unit
McGill University
Draft Agenda – Speakers and Times Subject to Change

9:30 a.m.  Richard Finkel  
Division Chief, Neurology  
Department of Pediatrics  
Nemours Children’s Health System

9:45 a.m.  Petra Kaufmann  
Vice President, R&D Translational Medicine  
AveXis

10:00 a.m.  Panel Discussion with Speakers and Workshop Participants

10:30 a.m.  Break

SESSION II: UNDERSTANDING THE COMPLEXITIES OF PATIENT SELECTION, ENROLLMENT, AND THE CONSENT PROCESS

Session Objectives:
- Understand ethical issues surrounding patient selection, enrollment, and consent for gene-based therapies and how they differ from conventional clinical trials.
- Identify what resources are available to help patients and providers accurately understand the potential risks and benefits of participating in a gene-based clinical trial.
- Explore communication strategies aimed at helping patients make informed decisions about participating in trials for gene-based therapies.

Session Moderator: Mildred Cho, Stanford University

10:45 a.m.  Courtney FitzHugh  
Lasker Clinical Research Scholar  
Laboratory of Early Sickle Mortality Prevention  
National Heart, Lung, and Blood Institute  
National Institutes of Health

11:00 a.m.  John Tisdale  
Senior Investigator and Director, Cellular and Molecular Therapeutics Laboratory  
National Heart, Lung, and Blood Institute  
National Institutes of Health

11:15 a.m.  Jennifer Puck  
Professor, Department of Pediatrics  
UCSF

11:30 a.m.  Pat Furlong  
Founding President and CEO  
Parent Project Muscular Dystrophy

11:45 a.m.  Ron Bartek

Patient and Family Perspectives
Draft Agenda – Speakers and Times Subject to Change

11:50 a.m. **MARIA JOSE CONTRERAS**

11:55 a.m. **TESHA SAMUELS**

12:00 p.m. **Panel Discussion with Speakers and Workshop Participants**

12:30 p.m. **Working Lunch**

**SESSION III: CONSIDERING THE CHALLENGES WITH DEVELOPING ENDPOINTS FOR GENE THERAPY CLINICAL TRIALS**

Session Objective:
- Learn about successes and challenges in accurately measuring clinical endpoints and outcomes for gene-based therapies and moving products through the translational pathway.

*Session Moderator: Larissa Lapteva, FDA*

1:30 p.m. **LARISSA LAPTEVA**
Associate Director for Clinical and Nonclinical Regulation, Division of Clinical Evaluation, Pharmacology, and Toxicology
Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)

1:45 p.m. **DWIGHT KOEBERL**
Professor, Department of Pediatrics/Division of Medical Genetics, and Department of Molecular Genetics and Metabolism
Medical Director, Biochemical Genetics Laboratory
Duke University

2:00 p.m. **ALBERT MAGUIRE**
Professor of Ophthalmology
Hospital of the University of Pennsylvania
Presbyterian Medical Center of Philadelphia

2:15 p.m. **JULIE KANTER**
Associate Professor, Hematology & Oncology
University of Alabama at Birmingham (UAB) School of Medicine

2:30 p.m. **Panel Discussion with Speakers and Workshop Participants**

3:00 p.m. **Break**
SESSION IV: INTEGRATING A GENE-BASED THERAPY INTO CLINICAL PRACTICE: EXPLORING LONG-TERM PATIENT MANAGEMENT AND FOLLOW-UP ISSUES

Session Objectives:

- Explore the implications of long-term clinical management of patients who participate in gene-based clinical trials (e.g., side effects, immunological implications).
- Discuss how data from a limited number of patients can be effectively utilized to determine if a gene-based therapy is safe and/or effective.

Session Moderator: Michael DeBaun, Vanderbilt University

3:15 p.m. Tejasri Purohit-Sheth
Director, Division of Clinical Evaluation, Pharmacology, and Toxicology
Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

3:30 p.m. Leslie Robison
Chair, Department of Epidemiology and Cancer Control
Co-Leader, Cancer Control & Survivorship Program
St. Jude Children’s Research Hospital

3:45 p.m. David Chonzi
Vice President, Pharmacovigilance and Epidemiology
Allogene

4:00 p.m. Bruce Marshall
Senior Vice President of Clinical Affairs
Cystic Fibrosis Foundation

4:15 p.m. Patient Perspective
Bob Levis

4:20 p.m. Panel Discussion with Speakers and Workshop Participants

SESSION V: NEXT STEPS & WRAP UP SESSION

Session Objectives:

- Discuss ways forward to support the clinical development of safe and effective gene-based therapies.
- Summarize the lessons learned and topics discussed throughout the workshop.

Session Moderator: Celia Witten, FDA

4:50 p.m. Final Panel Discussion

Ron Bartek
Mildred Cho
David Chonzi
**Draft Agenda – Speakers and Times Subject to Change**

**RICHARD FINKEL**  
**PAT FURLONG**  
**KATHERINE HIGH**  
**JULIE KANTER**

5:20 p.m.  **Final Remarks from Workshop Co-chairs**

CELIA WITTEN, *Workshop Co-Chair*  
Deputy Director, Center for Biologics Evaluation and Research  
U.S. Food and Drug Administration

5:30 p.m.  **Adjourn**  
**Evening Reception – 3rd Floor Atrium**